Filtered By:
Cancer: Squamous Cell Carcinoma
This page shows you your search results in order of date.
Order by Relevance | Date
Total 19037 results found since Jan 2013.
Research Progress of Metformin in the Treatment of Oral Squamous Cell Carcinoma
Endocrinology. 2023 Sep 20:bqad139. doi: 10.1210/endocr/bqad139. Online ahead of print.ABSTRACTOral squamous cell carcinoma (OSCC) is one of the most common malignancies with high mortality, posing a great threat to both human physical and mental health. With the advancement of scientific research, a variety of cancer therapies have been used for OSCC treatment. However, the prognosis of OSCC shows no significant improvement. Metformin has been recognized as the first-line drug for the treatment of diabetes, and recent studies have shown that metformin has a remarkable suppressive effect on tumor progression. Metformin can...
Source: Endocrinology - September 22, 2023 Category: Endocrinology Authors: Jiayi Liu Jing Zhao Xue Qiao Source Type: research
STAT3-EphA7 axis contributes to the progression of esophageal squamous cell carcinoma
CONCLUSION: Our results showed that the transcriptional expression of EphA7 was increased by activated STAT3, and the STAT3 signaling may act through EphA7 to promote the development of ESCC.PMID:37738252 | DOI:10.1080/0284186X.2023.2259601
Source: Acta Oncologica - September 22, 2023 Category: Cancer & Oncology Authors: Li Wang Qiao-Feng Zhao Bing-Bing Yang Hui-Jie Liang Xian-E Zhang Xiao-Yan Zhang Wan-Jing Yang Zhi-Yu Guo Xin Xu Fang Tian Qing-Hua Wu Source Type: research
Role of tissue markers associated with tumor microenvironment in the progression and immune suppression of oral squamous cell carcinoma
Med Oncol. 2023 Sep 20;40(10):303. doi: 10.1007/s12032-023-02169-5.ABSTRACTHead and neck cancers (HNC) continues to dominate major cancers contributing to mortality worldwide. Squamous cell carcinoma is the major type of HNC. Oral Squamous Cell Carcinoma grouped under HNC is a malignant tumor occurring in the oral cavity. The primary risk factors of OSCC are tobacco, alcohol consumption, etc. This review focuses on modulations, mechanisms, growth and differentiation of oral squamous cell carcinoma. Cancer cell surrounds itself with a group of elements forming a favorable environment known as tumor microenvironment (TME). I...
Source: Cancer Control - September 21, 2023 Category: Cancer & Oncology Authors: Suganya Ramalingam Sivaramakrishnan Shantha Susruthan Muralitharan Uma Sudhakar Harikrishnan Thamizhchelvan Venkatachalam Deepa Parvathi Source Type: research
Durable complete response to early immunotherapy discontinuation in a kidney transplant recipient with advanced cutaneous squamous cell carcinoma: A case report and review of literature
CONCLUSION: Organ transplant recipients with complete response to immunotherapy for cutaneous squamous cell carcinoma may continue to respond despite early treatment cessation. This may reduce the risks of late immune-related adverse events and acute graft rejection.PMID:37734447 | DOI:10.1016/j.trim.2023.101932
Source: Transplant Immunology - September 21, 2023 Category: Transplant Surgery Authors: Ziyao Lu Mohammed Afzal Keisuke Shirai Source Type: research
Different mechanisms of CD200-CD200R induce diverse outcomes in cancer treatment
Math Biosci. 2023 Sep 19:109072. doi: 10.1016/j.mbs.2023.109072. Online ahead of print.ABSTRACTThe CD200 is a cell membrane protein expressed by tumor cells, and its receptor CD200 receptor (CD200R) is expressed by immune cells including macrophages and dendritic cells. The formation of CD200-CD200R inhibits the cellular functions of the targeted immune cells, so CD200 is one type of the immune checkpoint and blockade CD200-CD200R formation is a potential cancer treatment. However, the CD200 blockade has opposite treatment outcomes in different types of cancers. For instance, the CD200R deficient mice have a higher tumor l...
Source: Mathematical Biosciences - September 21, 2023 Category: Statistics Authors: Kang-Ling Liao Kenton D Watt Tom Protin Source Type: research
Long non-coding RNA as a potential diagnostic biomarker in head and neck squamous cell carcinoma: A systematic review and meta-analysis
ConclusionsLncRNAs could be used as diagnostic biomarkers for HNSCC, but further investigation is needed to validate clinical efficacy and elucidate mechanisms. High-throughput sequencing and bioinformatics should be used to ascertain expression profiles.
Source: PLoS One - September 21, 2023 Category: Biomedical Science Authors: Mahdi Masrour Source Type: research
MEK inhibition induces expression of differentiation marker Keratin 10 in human keratinocytes
Pathol Res Pract. 2023 Sep 2;250:154788. doi: 10.1016/j.prp.2023.154788. Online ahead of print.ABSTRACTBRAF mutant metastatic melanoma was regularly treated in the past with a BRAF inhibitor (BRAFi) alone or in combination with inhibitors of the mitogen-activated protein kinase kinase (MEKi), which is still a common treatment. This combination therapy strongly reduced the occurrence of keratoacanthomas and squamous cell carcinoma, which was frequently seen when BRAFi was used as monotherapy. Here we addressed the question whether MEK inhibition counteracts squamous cell carcinoma development in part by promoting keratinocy...
Source: Pathology, Research and Practice - September 20, 2023 Category: Pathology Authors: F Karras M Bonsack S Seifert L Friedrich M Kunz Source Type: research
Neuroendocrine carcinoma of the cervix: About a rare case and literature review
CONCLUSION: To improve the survival of patients with large-cell neuroendocrine carcinomas of the uterine cervix, it is imperative to conduct multicenter clinical trials aimed at defining an effective, standardized treatment.PMID:37729821 | DOI:10.1016/j.ijscr.2023.108835
Source: Hand Surgery - September 20, 2023 Category: Surgery Authors: Imane El Abbassi S O Tanguara Y Bencherifi M Ennachit M Benhessou M El Kerroumi Source Type: research
MEK inhibition induces expression of differentiation marker Keratin 10 in human keratinocytes
Pathol Res Pract. 2023 Sep 2;250:154788. doi: 10.1016/j.prp.2023.154788. Online ahead of print.ABSTRACTBRAF mutant metastatic melanoma was regularly treated in the past with a BRAF inhibitor (BRAFi) alone or in combination with inhibitors of the mitogen-activated protein kinase kinase (MEKi), which is still a common treatment. This combination therapy strongly reduced the occurrence of keratoacanthomas and squamous cell carcinoma, which was frequently seen when BRAFi was used as monotherapy. Here we addressed the question whether MEK inhibition counteracts squamous cell carcinoma development in part by promoting keratinocy...
Source: Cell Research - September 20, 2023 Category: Cytology Authors: F Karras M Bonsack S Seifert L Friedrich M Kunz Source Type: research
Targeted therapy and immunotherapy for orbital and periorbital tumors: a major review
This article will focus on recent updates in the application of available targeted and immunotherapy for managing orbital and periorbital tumors and tumor-like conditions, which include cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, cutaneous melanoma, Merkel cell carcinoma, sebaceous gland carcinoma, solitary fibrous tumor, dermatofibrosarcoma protuberans, orbital meningioma, neurofibromatosis, Langerhans cell histiocytosis, ocular adnexal lymphoma, orbital lymphatic malformation, and adenoid cystic carcinoma.PMID:37728602 | DOI:10.1080/01676830.2023.2256848
Source: Orbit - September 20, 2023 Category: Opthalmology Authors: Emmanuel Lee Boniao Richard C Allen Gangadhara Sundar Source Type: research
Gene of the month: GATA3
J Clin Pathol. 2023 Sep 19:jcp-2023-209017. doi: 10.1136/jcp-2023-209017. Online ahead of print.ABSTRACTGATA binding protein 3 (GATA3) is a zinc-finger pioneer transcription factor involved in diverse processes. GATA3 regulates gene expression through binding nucleosomal DNA and facilitating chromatin remodelling. Post-translational modifications modulate its activity. During development, GATA3 plays a key role in cell differentiation. Mutations in GATA3 are linked to breast and bladder cancer. GATA3 expression is a feature of the luminal subtype of bladder cancer and has implications for immune status and therapeutic resp...
Source: Clinical Genitourinary Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Zekai Qiang Ibrahim Jubber Kirsty Lloyd Marcus Cumberbatch Jon Griffin Source Type: research
RT-qPCR Analysis of LAMP3 (CD208) Gene Expression in Oral Lichen Planus and Oral Squamous Cell Carcinoma
CONCLUSIONS: According to the findings of this study, it can be concluded that the expression of the LAMP3 gene in SCC lesions is higher than in healthy tissue. Hence, LAMP3 gene expression can be used as a diagnostic biomarker.PMID:37724152 | PMC:PMC10505466 | DOI:10.52547/rbmb.12.1.36
Source: Mol Biol Cell - September 19, 2023 Category: Molecular Biology Authors: Farnaz Mohajertehran Nooshin Mohtasham Mojtaba Ahmadi Mehdi Shahabinejad Maryam Mohammadi Source Type: research
Gene of the month: GATA3
J Clin Pathol. 2023 Sep 19:jcp-2023-209017. doi: 10.1136/jcp-2023-209017. Online ahead of print.ABSTRACTGATA binding protein 3 (GATA3) is a zinc-finger pioneer transcription factor involved in diverse processes. GATA3 regulates gene expression through binding nucleosomal DNA and facilitating chromatin remodelling. Post-translational modifications modulate its activity. During development, GATA3 plays a key role in cell differentiation. Mutations in GATA3 are linked to breast and bladder cancer. GATA3 expression is a feature of the luminal subtype of bladder cancer and has implications for immune status and therapeutic resp...
Source: Clinical Breast Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Zekai Qiang Ibrahim Jubber Kirsty Lloyd Marcus Cumberbatch Jon Griffin Source Type: research
Interactive effects of CDKN2B-AS1 gene polymorphism and habitual risk factors on oral cancer
J Cell Mol Med. 2023 Sep 19. doi: 10.1111/jcmm.17966. Online ahead of print.ABSTRACTOral squamous cell carcinoma (OSCC) is a common malignant disease associated with a high mortality rate and heterogeneous disease aetiology. Cyclin dependent kinase inhibitor 2B antisense RNA 1 (CDKN2B-AS1), is a long noncoding RNA that has been shown to act as a scaffold, sponge, or signal hub to promote carcinogenesis. Here, we attempted to assess the effect of CDKN2B-AS1 single-nucleotide polymorphisms (SNPs) on the susceptibility to OSCC. Five CDKN2B-AS1 SNPs, including rs564398, rs1333048, rs1537373, rs2151280 and rs8181047, were analy...
Source: Molecular Medicine - September 19, 2023 Category: Molecular Biology Authors: Jung-Chun Yeh Yi-Tzu Chen Ying-Erh Chou Shih-Chi Su Lun-Ching Chang Yen-Lin Chen Chiao-Wen Lin Shun-Fa Yang Source Type: research
